XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Unaudited Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 62,777 $ 24,194
Marketable securities 76,190 27,802
Prepaid expenses and other assets 5,535 2,596
Total current assets 144,502 54,592
Property and equipment, net 8,107 8,628
Right of use assets - operating leases 3,493 4,822
Restricted cash 30 0
Deferred financing costs   4,111
Total assets 156,132 72,153
Current liabilities:    
Accounts payable 4,614 1,728
Accrued expenses 10,187 10,361
Deferred revenue 2,136 2,459
Operating lease liabilities 2,597 3,437
Finance lease liabilities 1,188 1,162
Other current liabilities 755 523
Total current liabilities 21,477 19,670
Deferred revenues 45,000 45,000
Convertible promissory note   33,717
Derivative liability   5,739
Operating lease liabilities 948 976
Finance lease liabilities 740 872
Other long-term liabilities 1,897 1,041
Total liabilities 70,062 107,015
Commitments and contingencies
Convertible preferred stock   107,808
Stockholders' equity (deficit):    
Common stock $0.001 par value, 100,000,000 shares authorized, 40,254,666 and 2,217,737 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 40 2
Additional paid-in capital 268,759 1,197
Accumulated other comprehensive income (loss) 136 (41)
Accumulated deficit (182,865) (158,223)
Total Carisma Therapeutics Inc. stockholders' equity (deficit) 86,070 (157,065)
Noncontrolling interests   14,395
Total stockholders' equity (deficit) 86,070 (142,670)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 156,132 $ 72,153